Literature DB >> 27733785

Evaluation of hyaluronic acid, procollagen type III N-terminal peptide, and tissue inhibitor of matrix metalloproteinase-1 as serum markers of canine hepatic fibrosis.

Jonathan A Lidbury1, Aline Rodrigues Hoffmann1, Joanna K Fry1, Jan S Suchodolski1, Jörg M Steiner1.   

Abstract

The only way to diagnose hepatic fibrosis in dogs is by histological assessment of a liver biopsy specimen. As this technique is invasive and susceptible to sampling variation, serum biomarkers are used to detect hepatic fibrosis in humans. The objective of this study was to assess the utility of hyaluronic acid (HA), procollagen type III N-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) as serum markers of canine hepatic fibrosis. Serum samples were collected from 47 dogs with histologically confirmed hepatobiliary disease and 24 healthy dogs in order to measure concentrations of HA, PIIINP, and TIMP-1. Hepatic fibrosis was staged using a 5-point scoring scheme. There was no correlation between serum concentrations of HA or PIIINP and the severity of hepatic fibrosis. There was a negative correlation between serum concentration of TIMP-1 and the severity of hepatic fibrosis (rs = -0.33; P = 0.036). It was not possible to use serum concentrations of HA, PIIINP, or TIMP-1 to discriminate between dogs with absent-to-moderate hepatic fibrosis and those with marked-to-very-marked fibrosis. The results of this study do not support the utility of measuring serum concentrations of HA, PIIINP, or TIMP-1 for diagnosing canine hepatic fibrosis. Further studies are needed to support this finding.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27733785      PMCID: PMC5052882     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  22 in total

1.  Safety and efficacy of laparoscopic hepatic biopsy in dogs: 80 cases (2004-2009).

Authors:  Sarah L Petre; Janet Kovak McClaran; Philip J Bergman; Sebastien Monette
Journal:  J Am Vet Med Assoc       Date:  2012-01-15       Impact factor: 1.936

2.  Serum hyaluronic acid in dogs with congenital portosystemic shunts.

Authors:  M Seki; K Asano; M Sakai; N Kanno; K Teshima; K Edamura; S Tanaka
Journal:  J Small Anim Pract       Date:  2010-04-06       Impact factor: 1.522

Review 3.  Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis.

Authors:  M J Arthur; D A Mann; J P Iredale
Journal:  J Gastroenterol Hepatol       Date:  1998-09       Impact factor: 4.029

4.  Inflammatory, immunological, and intestinal disease biomarkers in Chinese Shar-Pei dogs with marked hypocobalaminemia.

Authors:  Niels Grützner; Romy M Heilmann; Shannon M Cranford; Andreas Holzenburg; Jan S Suchodolski; Jörg M Steiner
Journal:  J Vet Diagn Invest       Date:  2015-01       Impact factor: 1.279

5.  Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.

Authors:  S Ylisirniö; M Höyhtyä; T Turpeenniemi-Hujanen
Journal:  Anticancer Res       Date:  2000 Mar-Apr       Impact factor: 2.480

6.  Nutritional management of inherited copper-associated hepatitis in the Labrador retriever.

Authors:  Hille Fieten; Vincent C Biourge; Adrian L Watson; Peter A J Leegwater; Ted S G A M van den Ingh; Jan Rothuizen
Journal:  Vet J       Date:  2013-12-22       Impact factor: 2.688

7.  Suitability of using serum hialuronic acid concentrations in the diagnosis of canine liver fibrosis.

Authors:  K Glińska-Suchocka; A Orłowska; J Spużak; M Jankowski; K Kubiak
Journal:  Pol J Vet Sci       Date:  2015       Impact factor: 0.821

8.  Blood hyaluronic acid as a marker for canine cirrhosis.

Authors:  Hideyuki Kanemoto; Koichi Ohno; Manabu Sakai; Ko Nakashima; Masashi Takahashi; Yasuhito Fujino; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2009-09       Impact factor: 1.267

9.  Serum markers of liver fibrogenesis, and liver histology findings in patients with chronic liver diseases.

Authors:  J Holoman; J Glasa; S Galbavy; D Danis; A Molnarova; J Kazar; A Bednarova; J Misianik
Journal:  Bratisl Lek Listy       Date:  2002       Impact factor: 1.278

10.  A novel unstable duplication upstream of HAS2 predisposes to a breed-defining skin phenotype and a periodic fever syndrome in Chinese Shar-Pei dogs.

Authors:  Mia Olsson; Jennifer R S Meadows; Katarina Truvé; Gerli Rosengren Pielberg; Francesca Puppo; Evan Mauceli; Javier Quilez; Noriko Tonomura; Giordana Zanna; Maria José Docampo; Anna Bassols; Anne C Avery; Elinor K Karlsson; Anne Thomas; Daniel L Kastner; Erik Bongcam-Rudloff; Matthew T Webster; Armand Sanchez; Ake Hedhammar; Elaine F Remmers; Leif Andersson; Lluis Ferrer; Linda Tintle; Kerstin Lindblad-Toh
Journal:  PLoS Genet       Date:  2011-03-17       Impact factor: 5.917

View more
  4 in total

1.  Use of serum biomarkers in staging of canine hepatic fibrosis.

Authors:  Maud Menard; Alexis Lecoindre; Jean-Luc Cadoré; Michèle Chevallier; Aurélie Pagnon; Juan Hernandez; Rodolpho Oliveira Leal; Marine Hugonnard; Véronique Miette; Marie Destro; Benoît Rannou; Ghita Benchekroun; Patrick Lecoindre
Journal:  J Vet Diagn Invest       Date:  2019-07-26       Impact factor: 1.279

2.  Usefulness of noninvasive shear wave elastography for the assessment of hepatic fibrosis in dogs with hepatic disease.

Authors:  Masahiro Tamura; Hiroshi Ohta; Genya Shimbo; Tatsuyuki Osuga; Noboru Sasaki; Keitaro Morishita; Yumiko Kagawa; Mitsuyoshi Takiguchi
Journal:  J Vet Intern Med       Date:  2019-08-28       Impact factor: 3.333

Review 3.  Hepatic Fibrosis in Dogs.

Authors:  V M Eulenberg; J A Lidbury
Journal:  J Vet Intern Med       Date:  2017-11-30       Impact factor: 3.333

4.  Evaluation of potential serum biomarkers of hepatic fibrosis and necroinflammatory activity in dogs with liver disease.

Authors:  Chantel Raghu; Joanne Ekena; John M Cullen; Craig B Webb; Lauren A Trepanier
Journal:  J Vet Intern Med       Date:  2018-02-27       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.